查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1971822

新一代抗体疗法市场分析及预测（至2035年）：按类型、产品类型、技术、应用、製程、最终用户、开发阶段、实施类型、功能和模式划分

Next Generation Antibody Therapeutics Market Analysis and Forecast to 2035: Type, Product, Technology, Application, Process, End User, Stage, Deployment, Functionality, Mode
出版日期: | 出版商: Global Insight Services | 英文 336 Pages | 商品交期: 3-5个工作天内

价格
简介目录

预计新一代抗体疗法市场将从2024年的36亿美元成长到2034年的94亿美元，复合年增长率约为10.1%。新一代抗体疗法市场涵盖旨在提高疾病治疗的特异性、疗效和安全性的先进生物製药，包括双特异性抗体、抗体药物复合体和工程化抗体片段。在分子工程创新和精准医疗的推动下，该市场预计将在肿瘤学、免疫学和感染疾病取得重大进展，满足未被满足的医疗需求并拓展治疗应用。

新一代抗体疗法市场正经历强劲成长，这主要得益于生技和精准医疗的进步。单株抗体因其在多种疾病标靶治疗中的有效性而成为市场成长的主要驱动力。具有双重标靶化能力的双特异性抗体因其在肿瘤治疗方面的潜力而备受关注，并成为第二大增长领域。抗体药物复合体（ADC）也正在崛起，成为重要的细分市场，它将抗体的特异性与强效细胞毒性药物结合。肿瘤领域仍然是成长最快的领域，反映出对创新癌症治疗方法的迫切需求。自体免疫疾病领域紧随其后，这主要得益于旨在调节免疫反应的新型抗体疗法的开发。抗体设计和生产技术的改进等技术进步正在加速市场成长。对个人化医疗的日益重视正在推动对客製化抗体疗法的需求。製药公司之间的策略联盟和伙伴关係正在促进创新并拓展治疗产品线。监管支持和加速核准流程进一步强化了市场动态，促进了新型抗体疗法的上市。

市场区隔
按类型 单株抗体、双特异性抗体、抗体药物复合体、抗体片段、多多株抗体
产品 治疗性抗体、诊断性抗体、研究性抗体、抗体片段
科技 噬菌体展示、融合瘤、基因转殖小鼠、细菌展示、酵母展示、哺乳动物细胞展示
应用领域 肿瘤科、自体免疫疾病、感染疾病、心血管疾病、神经系统疾病、代谢性疾病
过程 药物发现、开发、生产、品管和监管核准
最终用户 製药公司、生技公司、研究机构、受託研究机构
步 临床前研究、临床试验与商业化
部署 内部、外包
功能 标靶治疗、免疫疗法、合併疗法
给药途径 静脉注射、皮下注射、肌肉注射和口服给药

市场概况：

新一代抗体疗法市场正经历着剧烈的变革，创新公司推出的尖端疗法占据了市场份额的主导地位。定价策略竞争激烈，反映出市场对更有效、更具标靶性的治疗方法的迫切需求。随着各公司努力满足未被满足的医疗需求并提高疗效，新产品上市数量迅速成长，市场呈现这样的特征。旨在加速产品开发和市场准入的策略联盟和伙伴关係进一步加剧了这种竞争格局。从竞争标竿分析的角度来看，主要参与者不断创新以保持其竞争优势。监管政策对市场产生了重大影响，北美和欧洲的严格监管准则影响市场动态。监管环境正在不断演变，以促进疗法开发，并强调透明度和安全性，各公司正在大力投资研发，以有效遵守这些法规。随着市场的成熟，抗体工程和新型递送平台的进步有望推动市场显着成长，并为相关人员带来丰厚的盈利机会。

主要趋势和驱动因素：

新一代抗体疗法市场正经历强劲成长，这主要得益于生技和个人化医疗的突破性进展。关键趋势包括双特异性抗体的开发，这种抗体能够增强标靶化能力和治疗效果。抗体药物复合体（ADC）的兴起正在革新癌症治疗，它能将细胞毒性药物直接递送至癌细胞，并最大限度地减少副作用。此外，为了满足对标靶治疗的需求，用于治疗自体免疫疾病的单株抗体也日益受到关注。推动因素包括抗体工程技术的进步和慢性病的日益增加。监管核准的加快为市场扩张创造了有利环境。此外，生物技术公司与研究机构之间的合作正在促进创新并加速开发平臺。新兴市场蕴藏着许多机会，这些市场的医疗基础设施正在不断完善，对先进疗法的需求也不断增长。那些投资于扎实研发和策略伙伴关係的公司将更有能力掌握这些快速成长的机会。

限制与挑战：

新一代抗体疗法市场面临许多重大限制和挑战。其中一个主要限制因素是高昂的研发和生产成本，这可能成为中小企业进入市场的壁垒，并限制其市场准入。这种财务壁垒往往导致市场力量集中在少数几家大型公司手中，扼杀创新。监管障碍也是一项重大挑战。新疗法的严格核准流程会延缓市场进入并增加成本。这种法规环境要求进行大规模的临床试验。抗体生产的复杂性也是一大挑战。生产这些疗法需要先进的技术和专业知识，并且难以有效率地扩大规模。这种复杂性可能导致产品品质不稳定和供应链问题。传统治疗方法的竞争进一步阻碍了市场渗透。许多医疗服务提供者和患者仍然忠于现有治疗方法，从而减缓了新型抗体疗法的普及。最后，智慧财产权和专利纠纷也会阻碍市场成长。竞争格局中充斥着围绕专有技术的法律纠纷，这分散了研发资源。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 单株抗体
    • 双特异性抗体
    • 抗体药物复合体
    • 抗体片段
    • 多株抗体
  • 市场规模及预测：依产品划分
    • 治疗性抗体
    • 诊断抗体
    • 研究抗体
    • 抗体片段
  • 市场规模及预测：依技术划分
    • 噬菌体展示
    • 融合瘤
    • 基因改造小鼠
    • 细菌展示
    • 酵母展示
    • 哺乳动物细胞展示
  • 市场规模及预测：依应用领域划分
    • 肿瘤学
    • 自体免疫疾病
    • 感染疾病
    • 心血管疾病
    • 神经系统疾病
    • 代谢性疾病
  • 市场规模及预测：依製程划分
    • 药物发现
    • 发展
    • 製造业
    • 品管
    • 监管部门核准
  • 市场规模及预测：依最终用户划分
    • 製药公司
    • 生技公司
    • 研究所
    • 合约研究机构
  • 市场规模及预测：依发展阶段划分
    • 临床前阶段
    • 临床试验
    • 已上市
  • 市场规模及预测：依发展状况
    • 内部开发
    • 外包
  • 市场规模及预测：依功能划分
    • 标靶治疗
    • 免疫疗法
    • 加入
  • 市场规模及预测：依管理途径
    • 静脉注射
    • 皮下注射
    • 肌肉内注射
    • 口服

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章 公司简介

  • MacroGenics
  • ImmunoGen
  • MorphoSys
  • Genmab
  • Pieris Pharmaceuticals
  • AbCellera
  • Xencor
  • Adimab
  • MabSpace Biosciences
  • Harbour BioMed
  • Zymeworks
  • Bicycle Therapeutics
  • Crescendo Biologics
  • Mabion
  • I-Mab

第九章：关于我们

简介目录
Product Code: GIS34082

Next Generation Antibody Therapeutics Market is anticipated to expand from $3.6 billion in 2024 to $9.4 billion by 2034, growing at a CAGR of approximately 10.1%. The Next Generation Antibody Therapeutics Market encompasses advanced biologic drugs engineered to enhance specificity, efficacy, and safety in treating diseases. This includes bispecific antibodies, antibody-drug conjugates, and engineered antibody fragments. Driven by innovations in molecular engineering and a focus on precision medicine, this market promises significant advancements in oncology, immunology, and infectious diseases, addressing unmet medical needs and expanding therapeutic applications.

The Next Generation Antibody Therapeutics Market is experiencing robust growth, propelled by advancements in biotechnology and precision medicine. Monoclonal antibodies lead the market, driven by their efficacy in targeted therapies for various diseases. Bispecific antibodies, offering dual-targeting capabilities, are the second-highest performing sub-segment, gaining traction for their potential in oncology treatments. Antibody-drug conjugates are also emerging as a critical segment, combining antibody specificity with potent cytotoxic agents. The oncology therapeutic area remains the top-performing segment, reflecting the high demand for innovative cancer treatments. Autoimmune diseases follow, benefiting from the development of novel antibody therapies aimed at modulating immune responses. Technological advancements, such as improved antibody engineering and production techniques, are accelerating market growth. The increasing focus on personalized medicine is driving demand for tailored antibody therapies. Strategic collaborations and partnerships among pharmaceutical companies are fostering innovation and expanding the therapeutic pipeline. Regulatory support and expedited approval processes further enhance market dynamics, facilitating the introduction of novel antibody therapeutics.

Market Segmentation
TypeMonoclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates, Antibody Fragments, Polyclonal Antibodies
ProductTherapeutic Antibodies, Diagnostic Antibodies, Research Antibodies, Antibody Fragments
TechnologyPhage Display, Hybridoma, Transgenic Mouse, Bacterial Display, Yeast Display, Mammalian Cell Display
ApplicationOncology, Autoimmune Diseases, Infectious Diseases, Cardiovascular Diseases, Neurological Diseases, Metabolic Diseases
ProcessDiscovery, Development, Manufacturing, Quality Control, Regulatory Approval
End UserPharmaceutical Companies, Biotechnology Companies, Research Institutes, Contract Research Organizations
StagePreclinical, Clinical Trials, Commercialized
DeploymentIn-House, Outsourced
FunctionalityTargeted Therapy, Immunotherapy, Conjugation
ModeIntravenous, Subcutaneous, Intramuscular, Oral

Market Snapshot:

Next Generation Antibody Therapeutics Market is witnessing a dynamic shift, with market share being dominated by innovative companies launching advanced therapeutics. Pricing strategies remain competitive, reflecting the high demand for more effective and targeted treatments. The market is characterized by a surge in new product launches, as companies strive to address unmet medical needs and enhance therapeutic efficacy. This competitive landscape is further invigorated by strategic collaborations and partnerships that aim to accelerate product development and market entry. In terms of competition benchmarking, key players are continuously innovating to maintain their competitive edge. Regulatory influences play a significant role, with stringent guidelines in North America and Europe impacting market dynamics. The regulatory landscape is evolving, encouraging transparency and safety in therapeutic development. Companies are investing heavily in research and development to navigate these regulations effectively. As the market continues to mature, advancements in antibody engineering and novel delivery platforms are expected to drive substantial growth, offering lucrative opportunities for stakeholders.

Geographical Overview:

The Next Generation Antibody Therapeutics Market is witnessing robust growth across various regions, each presenting unique opportunities. North America leads the market, propelled by substantial investments in biotechnology and a strong focus on innovative therapeutic solutions. The presence of major pharmaceutical companies and research institutions further bolsters the region's market dominance. Europe follows closely, with significant government support for biotechnological research and a well-established healthcare infrastructure. The region's emphasis on personalized medicine and advanced therapeutics enhances its market potential. In Asia Pacific, the market is expanding rapidly, driven by increasing healthcare expenditure and a growing focus on precision medicine. Countries like China and India are emerging as key players, with rising investments in biopharmaceutical research and development. Latin America and the Middle East & Africa are burgeoning markets with increasing potential. Brazil and Saudi Arabia are witnessing a surge in biotechnology investments, recognizing the importance of next-generation antibody therapeutics in advancing healthcare outcomes.

Key Trends and Drivers:

The Next Generation Antibody Therapeutics Market is experiencing robust growth driven by breakthroughs in biotechnology and personalized medicine. Key trends include the development of bispecific antibodies, which enhance targeting capabilities and therapeutic efficacy. The rise of antibody-drug conjugates (ADCs) is revolutionizing cancer treatment by delivering cytotoxic agents directly to cancer cells, minimizing collateral damage. The market is also witnessing an increased focus on monoclonal antibodies for autoimmune diseases, reflecting the demand for targeted therapies. Drivers include technological advancements in antibody engineering and a growing prevalence of chronic diseases. Regulatory approvals are accelerating, providing a favorable landscape for market expansion. Moreover, collaborations between biotech firms and research institutions are fostering innovation and expediting the development pipeline. Opportunities abound in emerging markets, where healthcare infrastructure is improving, and demand for advanced therapeutics is rising. Companies investing in robust R&D and strategic partnerships are well-positioned to capitalize on these burgeoning opportunities.

Restraints and Challenges:

The Next Generation Antibody Therapeutics Market is confronted with several significant restraints and challenges. One primary restraint is the high cost of development and production, which can be prohibitive for smaller companies and limit market entry. This financial barrier often results in a concentration of market power among a few large players, stifling innovation. Regulatory hurdles present another formidable challenge. The stringent approval processes for new therapeutics can delay market entry and increase costs. This regulatory environment demands extensive clinical trials, which are both time-consuming and expensive. The complexity of antibody production also poses a challenge. Manufacturing these therapeutics requires advanced technology and expertise, which can be difficult to scale efficiently. This complexity can lead to variability in product quality and supply chain issues. Market penetration is further hindered by competition from traditional therapies. Many healthcare providers and patients remain loyal to established treatments, slowing the adoption of new antibody therapeutics. Lastly, intellectual property and patent disputes can impede market growth. The competitive landscape is fraught with legal battles over proprietary technologies, diverting resources from research and development.

Key Players:

MacroGenics, ImmunoGen, MorphoSys, Genmab, Pieris Pharmaceuticals, AbCellera, Xencor, Adimab, MabSpace Biosciences, Harbour BioMed, Zymeworks, Bicycle Therapeutics, Crescendo Biologics, Mabion, I-Mab

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Application
  • 2.5 Key Market Highlights by Process
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Stage
  • 2.8 Key Market Highlights by Deployment
  • 2.9 Key Market Highlights by Functionality
  • 2.10 Key Market Highlights by Mode

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Monoclonal Antibodies
    • 4.1.2 Bispecific Antibodies
    • 4.1.3 Antibody-Drug Conjugates
    • 4.1.4 Antibody Fragments
    • 4.1.5 Polyclonal Antibodies
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Therapeutic Antibodies
    • 4.2.2 Diagnostic Antibodies
    • 4.2.3 Research Antibodies
    • 4.2.4 Antibody Fragments
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 Phage Display
    • 4.3.2 Hybridoma
    • 4.3.3 Transgenic Mouse
    • 4.3.4 Bacterial Display
    • 4.3.5 Yeast Display
    • 4.3.6 Mammalian Cell Display
  • 4.4 Market Size & Forecast by Application (2020-2035)
    • 4.4.1 Oncology
    • 4.4.2 Autoimmune Diseases
    • 4.4.3 Infectious Diseases
    • 4.4.4 Cardiovascular Diseases
    • 4.4.5 Neurological Diseases
    • 4.4.6 Metabolic Diseases
  • 4.5 Market Size & Forecast by Process (2020-2035)
    • 4.5.1 Discovery
    • 4.5.2 Development
    • 4.5.3 Manufacturing
    • 4.5.4 Quality Control
    • 4.5.5 Regulatory Approval
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Pharmaceutical Companies
    • 4.6.2 Biotechnology Companies
    • 4.6.3 Research Institutes
    • 4.6.4 Contract Research Organizations
  • 4.7 Market Size & Forecast by Stage (2020-2035)
    • 4.7.1 Preclinical
    • 4.7.2 Clinical Trials
    • 4.7.3 Commercialized
  • 4.8 Market Size & Forecast by Deployment (2020-2035)
    • 4.8.1 In-House
    • 4.8.2 Outsourced
  • 4.9 Market Size & Forecast by Functionality (2020-2035)
    • 4.9.1 Targeted Therapy
    • 4.9.2 Immunotherapy
    • 4.9.3 Conjugation
  • 4.10 Market Size & Forecast by Mode (2020-2035)
    • 4.10.1 Intravenous
    • 4.10.2 Subcutaneous
    • 4.10.3 Intramuscular
    • 4.10.4 Oral

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Application
      • 5.2.1.5 Process
      • 5.2.1.6 End User
      • 5.2.1.7 Stage
      • 5.2.1.8 Deployment
      • 5.2.1.9 Functionality
      • 5.2.1.10 Mode
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Application
      • 5.2.2.5 Process
      • 5.2.2.6 End User
      • 5.2.2.7 Stage
      • 5.2.2.8 Deployment
      • 5.2.2.9 Functionality
      • 5.2.2.10 Mode
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Application
      • 5.2.3.5 Process
      • 5.2.3.6 End User
      • 5.2.3.7 Stage
      • 5.2.3.8 Deployment
      • 5.2.3.9 Functionality
      • 5.2.3.10 Mode
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Application
      • 5.3.1.5 Process
      • 5.3.1.6 End User
      • 5.3.1.7 Stage
      • 5.3.1.8 Deployment
      • 5.3.1.9 Functionality
      • 5.3.1.10 Mode
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Application
      • 5.3.2.5 Process
      • 5.3.2.6 End User
      • 5.3.2.7 Stage
      • 5.3.2.8 Deployment
      • 5.3.2.9 Functionality
      • 5.3.2.10 Mode
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Application
      • 5.3.3.5 Process
      • 5.3.3.6 End User
      • 5.3.3.7 Stage
      • 5.3.3.8 Deployment
      • 5.3.3.9 Functionality
      • 5.3.3.10 Mode
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Application
      • 5.4.1.5 Process
      • 5.4.1.6 End User
      • 5.4.1.7 Stage
      • 5.4.1.8 Deployment
      • 5.4.1.9 Functionality
      • 5.4.1.10 Mode
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Application
      • 5.4.2.5 Process
      • 5.4.2.6 End User
      • 5.4.2.7 Stage
      • 5.4.2.8 Deployment
      • 5.4.2.9 Functionality
      • 5.4.2.10 Mode
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Application
      • 5.4.3.5 Process
      • 5.4.3.6 End User
      • 5.4.3.7 Stage
      • 5.4.3.8 Deployment
      • 5.4.3.9 Functionality
      • 5.4.3.10 Mode
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Application
      • 5.4.4.5 Process
      • 5.4.4.6 End User
      • 5.4.4.7 Stage
      • 5.4.4.8 Deployment
      • 5.4.4.9 Functionality
      • 5.4.4.10 Mode
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Application
      • 5.4.5.5 Process
      • 5.4.5.6 End User
      • 5.4.5.7 Stage
      • 5.4.5.8 Deployment
      • 5.4.5.9 Functionality
      • 5.4.5.10 Mode
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Application
      • 5.4.6.5 Process
      • 5.4.6.6 End User
      • 5.4.6.7 Stage
      • 5.4.6.8 Deployment
      • 5.4.6.9 Functionality
      • 5.4.6.10 Mode
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Application
      • 5.4.7.5 Process
      • 5.4.7.6 End User
      • 5.4.7.7 Stage
      • 5.4.7.8 Deployment
      • 5.4.7.9 Functionality
      • 5.4.7.10 Mode
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Application
      • 5.5.1.5 Process
      • 5.5.1.6 End User
      • 5.5.1.7 Stage
      • 5.5.1.8 Deployment
      • 5.5.1.9 Functionality
      • 5.5.1.10 Mode
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Application
      • 5.5.2.5 Process
      • 5.5.2.6 End User
      • 5.5.2.7 Stage
      • 5.5.2.8 Deployment
      • 5.5.2.9 Functionality
      • 5.5.2.10 Mode
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Application
      • 5.5.3.5 Process
      • 5.5.3.6 End User
      • 5.5.3.7 Stage
      • 5.5.3.8 Deployment
      • 5.5.3.9 Functionality
      • 5.5.3.10 Mode
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Application
      • 5.5.4.5 Process
      • 5.5.4.6 End User
      • 5.5.4.7 Stage
      • 5.5.4.8 Deployment
      • 5.5.4.9 Functionality
      • 5.5.4.10 Mode
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Application
      • 5.5.5.5 Process
      • 5.5.5.6 End User
      • 5.5.5.7 Stage
      • 5.5.5.8 Deployment
      • 5.5.5.9 Functionality
      • 5.5.5.10 Mode
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Application
      • 5.5.6.5 Process
      • 5.5.6.6 End User
      • 5.5.6.7 Stage
      • 5.5.6.8 Deployment
      • 5.5.6.9 Functionality
      • 5.5.6.10 Mode
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Application
      • 5.6.1.5 Process
      • 5.6.1.6 End User
      • 5.6.1.7 Stage
      • 5.6.1.8 Deployment
      • 5.6.1.9 Functionality
      • 5.6.1.10 Mode
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Application
      • 5.6.2.5 Process
      • 5.6.2.6 End User
      • 5.6.2.7 Stage
      • 5.6.2.8 Deployment
      • 5.6.2.9 Functionality
      • 5.6.2.10 Mode
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Application
      • 5.6.3.5 Process
      • 5.6.3.6 End User
      • 5.6.3.7 Stage
      • 5.6.3.8 Deployment
      • 5.6.3.9 Functionality
      • 5.6.3.10 Mode
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Application
      • 5.6.4.5 Process
      • 5.6.4.6 End User
      • 5.6.4.7 Stage
      • 5.6.4.8 Deployment
      • 5.6.4.9 Functionality
      • 5.6.4.10 Mode
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Application
      • 5.6.5.5 Process
      • 5.6.5.6 End User
      • 5.6.5.7 Stage
      • 5.6.5.8 Deployment
      • 5.6.5.9 Functionality
      • 5.6.5.10 Mode

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 MacroGenics
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 ImmunoGen
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 MorphoSys
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Genmab
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Pieris Pharmaceuticals
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 AbCellera
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Xencor
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Adimab
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 MabSpace Biosciences
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Harbour BioMed
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Zymeworks
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Bicycle Therapeutics
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Crescendo Biologics
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Mabion
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 I-Mab
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us